On the morning of November 27, the China Research on Reducing the Incidence of Liver Cancer in Hepatitis B Patients (Oasis) Project Promotion Conference was held in Fuzhou, aiming to promote scientific research on the prevention and treatment of hepatitis B and effectively reduce the incidence and mortality rate of hepatocellular carcinoma caused by chronic hepatitis B.
Liver cancer is the fourth incidence in China, the second in mortality of malignant tumors, China's liver cancer patients caused by HBV accounted for 84% -92%, the World Health Organization's International Agency for Research on Cancer also identified HBV as a class 1 carcinogen. The lifetime prevalence of liver cancer in HBV carriers is as high as about 15%, and the incidence of liver cancer in patients with chronic hepatitis B is 14-223 times that of non-carriers of HBV. Therefore, liver cancer caused by HBV infection will be one of the main medical burdens facing our country. The "China Research Project on Reducing the Incidence of Liver Cancer in Hepatitis B Patients (Oasis) Project" is a prospective cohort study to reduce the incidence of HBV-related liver cancer, which is of great significance for optimizing the antiviral treatment plan for chronic hepatitis B and further reducing the incidence of liver cancer in Chinese hepatitis B patients.
On the day of the promotion meeting, Professor Zhu Yueyong of the First Affiliated Hospital of Fujian Medical University presided over the speech, Secretary Lin Zhangya of the First Affiliated Hospital of Fujian Medical University delivered a speech, Yang Xizhong, Executive Vice President of the China Hepatitis Prevention and Control Foundation, delivered a speech online, Professor Zhang Wenhong of Huashan Hospital Affiliated to Fudan University made a keynote speech on "National Progress of oasis project", Professor Sun Jiamin of the Second Hospital of Longyan City made a keynote speech on "Assessment and Treatment of High-risk Groups with Liver Cancer"; Professor Xue Xiulan of the First Affiliated Hospital of Xiamen University made a keynote speech Keynote speech on histological improvement of liver in patients with slow hepatitis B after interferon therapy;
On the afternoon of November 27, the China Slow Hepatitis B Clinical Cure (Everest) Project was held in Fuzhou, the largest slow hepatitis B public welfare project in China. The theme of the conference was "Active Prevention, Active Detection, Standardized Treatment, and Comprehensive Containment of Hepatitis Hazards".
On the day of the promotion meeting, Professor Jiang Jiaji of the First Affiliated Hospital of Fujian Medical University presided over the meeting, Gao Zhiliang of the Third Affiliated Hospital of Sun Yat-sen University introduced the "Phased Progress of the 3rd Anniversary of the Clinical Cure (Everest) Project of Chronic Hepatitis B in China"; Zhu Yueyong, Administrative Director of the Department of Hepatology of the Liver Disease Center of the First Affiliated Hospital of Fujian Medical University and Director of the Institute of Liver Disease of Fujian Medical University, made the "Progress Report on the Fujian Stage of the Clinical Cure (Everest) Project of China Chronic Hepatitis B". Zhao Haidong, director of the Department of Infectious Diseases of Xiamen Chang Gung Hospital, made a presentation on "Sharing Clinical Cure Experience of IHC Patients"; Professor Zeng Dawu of the First Affiliated Hospital of Fujian Medical University made a presentation on "Sharing everest cases".
In addition, the meeting also presented awards to the First Affiliated Hospital of Fujian Medical University, the Mengchao Hepatobiliary Hospital of Fujian Medical University, and the First Affiliated Hospital of Xiamen University, which won the fujian slow hepatitis B clinical cure (Everest) project in China. At the same time, 6 new Everest sub-central hospitals in Fujian were awarded (Jinjiang City Hospital, Putian First Hospital, Jian'ou Municipal Hospital, Nanping Jianyang First Hospital, Shaowu Municipal Hospital, Fuqing Municipal Hospital).
The event was initiated by the China Hepatitis Prevention and Control Foundation, and the Oasis Project was supported by Huashan Hospital affiliated to Fudan University. The Everest project is supported by the Third Affiliated Hospital of Sun Yat-sen University.